WVE Logo

Wave Life Sciences Ltd. (WVE) 

NASDAQ
Market Cap
$2.19B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
7 of 776
Rank in Industry
7 of 433

Largest Insider Buys in Sector

WVE Stock Price History Chart

WVE Stock Performance

About Wave Life Sciences Ltd.

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin …

Insider Activity of Wave Life Sciences Ltd.

Over the last 12 months, insiders at Wave Life Sciences Ltd. have bought $43.84M and sold $4.74M worth of Wave Life Sciences Ltd. stock.

On average, over the past 5 years, insiders at Wave Life Sciences Ltd. have bought $43.84M and sold $2.25M worth of stock each year.

Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $125M. GSK plc (10 percent owner) — $38.84M.

The last purchase of 2,791,930 shares for transaction amount of $22.34M was made by GSK plc (10 percent owner) on 2024‑09‑27.

List of Insider Buy and Sell Transactions, Wave Life Sciences Ltd.

2024-10-16SalePresident and CEO
90,474
0.1357%
$15.00$1.36M-2.92%
2024-10-16SaleSee Remarks
208,836
0.2854%
$13.67$2.86M-2.92%
2024-09-27Purchase10 percent owner
2.79M
2.2327%
$8.00$22.34M+5.31%
2024-09-25SaleChief Financial Officer
17,146
0.0232%
$9.00$154,3140.00%
2024-08-21SalePresident and CEO
48,366
0.0383%
$5.78$279,555+36.75%
2024-04-03SaleChief Financial Officer
15,630
0.0133%
$6.17$96,421-0.51%
2023-12-11Purchase
1M
1.2134%
$5.00$5M+37.89%
2023-12-07Purchase10 percent owner
3.3M
3.4922%
$5.00$16.5M+20.21%
2023-08-23SaleChief Financial Officer
37,062
0.0365%
$4.75$176,119+10.31%
2023-02-16SalePresident and CEO
29,400
0.0251%
$4.04$118,776-5.01%
2023-02-16SaleSee Remarks
10,249
0.0087%
$4.03$41,303-5.01%
2023-02-16SaleChief Financial Officer
9,729
0.0083%
$4.04$39,305-5.01%
2023-02-16SaleSee Remarks
10,258
0.0087%
$4.03$41,340-5.01%
2022-05-04SalePresident and CEO
33,501
0.0447%
$1.72$57,622+106.19%
2022-05-04SaleSee Remarks
16,714
0.0223%
$1.72$28,748+106.19%
2022-05-04SaleSee Remarks
16,714
0.0223%
$1.72$28,748+106.19%
2022-05-04SaleSee Remarks
10,867
0.0145%
$1.72$18,691+106.19%
2022-05-04SaleChief Financial Officer
5,021
0.0067%
$1.72$8,636+106.19%
2022-02-16SalePresident and CEO
33,150
0.0438%
$2.32$76,908+18.28%
2022-02-16SaleChief Technology Officer
10,603
0.014%
$2.32$24,599+18.28%

Insider Historical Profitability

29.03%
RA CAPITAL MANAGEMENT, L.P.
18202009
11.7488%
$14.1560+47.04%
GSK plc10 percent owner
16775691
10.8281%
$14.1520
Tanaka Masaharu
2774118
1.7906%
$14.1523+2.01%
TAKANASHI KEN
1984130
1.2807%
$14.1520+2.01%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RA Capital Management, L.P.$112.31M14.8618.2M0%+$00.11
Maverick Capital Ltd$47.44M6.287.69M-8.99%-$4.69M0.92
M28 Capital Management Lp$43.19M5.727M-5.06%-$2.3M31.91
BlackRock$39.34M5.216.38M+18.8%+$6.23M<0.01
683 Capital Management Llc$33.01M4.375.35M-4.46%-$1.54M3.58
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.